Literature DB >> 9128291

Relation of apolipoprotein E polymorphism to lipid metabolism in obese children.

G Parlier1, G Thomas, G Bereziat, J L Fontaine, J P Girardet.   

Abstract

To determine whether the risk of obesity-associated dyslipidemia in children is influenced by apolipoprotein E (apoE) polymorphism, we studied 137 obese, nongenetically related children aged 2.2-14.4 y (mean age, 9.9 +/- 3.1 y) with a weight-for-height excess of 43.7 +/- 17.9%. The apoE genotype was determined by studying specific DNA restriction patterns. Total cholesterol, HDL-cholesterol, and triglycerides were assayed in plasma before dietary treatment initiation. ApoE allele and phenotype distributions were comparable to those reported in the Caucasian population at large. Fifty-five children (41%) had elevated lipid levels. Compared with obese children with the epsilon3 or epsilon4 allele, those with the epsilon2 allele were more likely to have hypertriglyceridemia (19.5% versus 52.9%, p < 0.05) and had a higher mean triglyceride level: children with the epsilon4 allele were more likely to have a LDL-cholesterol elevation (34.7% versus 13.4%, p < 0.05). Our data demonstrate that, even in childhood, obesity is associated with a marked increase in the risk of lipoprotein abnormalities and that the latter are influenced by apoE polymorphism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9128291     DOI: 10.1203/00006450-199705000-00013

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  3 in total

1.  The apolipoprotein E gene and Taq1A polymorphisms in childhood obesity.

Authors:  Mehmet Ali Ergun; Meral Yirmibes Karaoguz; Altug Koc; Orhun Camurdan; Aysun Bideci; A Canan Yazici; Peyami Cinaz
Journal:  Genet Test Mol Biomarkers       Date:  2010-06

Review 2.  Should pediatric patients with hyperlipidemia receive drug therapy?

Authors:  Deepak Bhatnagar
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Diversity of apolipoprotein E genetic polymorphism significance on cardiovascular risk is determined by the presence of metabolic syndrome among hypertensive patients.

Authors:  Andrei Alkmim Teixeira; Mauro Sergio Marrocos; Beata Marie Redublo Quinto; Maria Aparecida Dalboni; Cassio Jose de Oliveira Rodrigues; Silmara de Melo Carmona; Mariana Kuniyoshi; Marcelo Costa Batista
Journal:  Lipids Health Dis       Date:  2014-11-20       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.